Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084340632> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2084340632 endingPage "264" @default.
- W2084340632 startingPage "259" @default.
- W2084340632 abstract "Sunitinib, an orally multitargeted tyrosine kinase inhibitor and standard first-line treatment for metastatic renal cell carcinoma, is usually administered on a 6-week schedule. Toxicities reported with this drug are usually of moderate grade, which results in good treatment tolerability and patients' compliance. However, in some cases high-grade or prolonged toxicities require temporary treatment interruption or dose adjustment, possibly resulting in reduced treatment efficacy. We describe three cases of metastatic renal cell carcinoma patients (a 53-year-old male, a 70-year-old woman, and a 65-year-old woman) who received a shortened 3-week sunitinib administration schedule, 2 weeks daily administration followed by 1 week of rest (2/1) due to toxicities developed on the classic 6-week schedule, which would have required a temporary treatment interruption or a dose reduction. Treatment was generally well tolerated with manageable toxicities. A 3-week administration schedule of sunitinib may represent a valid alternative for managing toxicity while maintaining the planned dose intensity over a 6-weeks period of time. Sunitinib may thus be administered using a flexible dosing schedule to meet individual patient needs, achieving better tolerability and maintaining significant response to treatment." @default.
- W2084340632 created "2016-06-24" @default.
- W2084340632 creator A5008491982 @default.
- W2084340632 creator A5013419207 @default.
- W2084340632 creator A5018027566 @default.
- W2084340632 creator A5055228504 @default.
- W2084340632 creator A5057008368 @default.
- W2084340632 creator A5063122523 @default.
- W2084340632 creator A5068279218 @default.
- W2084340632 date "2012-05-01" @default.
- W2084340632 modified "2023-09-26" @default.
- W2084340632 title "The Efficacy and Tolerability of a Sunitinib 3-Week Administration Schedule in Metastatic Renal Cell Carcinoma Patients: Report of Three Cases" @default.
- W2084340632 doi "https://doi.org/10.3727/096504013x13589503482851" @default.
- W2084340632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23581233" @default.
- W2084340632 hasPublicationYear "2012" @default.
- W2084340632 type Work @default.
- W2084340632 sameAs 2084340632 @default.
- W2084340632 citedByCount "5" @default.
- W2084340632 countsByYear W20843406322013 @default.
- W2084340632 countsByYear W20843406322014 @default.
- W2084340632 countsByYear W20843406322016 @default.
- W2084340632 countsByYear W20843406322020 @default.
- W2084340632 crossrefType "journal-article" @default.
- W2084340632 hasAuthorship W2084340632A5008491982 @default.
- W2084340632 hasAuthorship W2084340632A5013419207 @default.
- W2084340632 hasAuthorship W2084340632A5018027566 @default.
- W2084340632 hasAuthorship W2084340632A5055228504 @default.
- W2084340632 hasAuthorship W2084340632A5057008368 @default.
- W2084340632 hasAuthorship W2084340632A5063122523 @default.
- W2084340632 hasAuthorship W2084340632A5068279218 @default.
- W2084340632 hasBestOaLocation W20843406321 @default.
- W2084340632 hasConcept C121608353 @default.
- W2084340632 hasConcept C126322002 @default.
- W2084340632 hasConcept C141071460 @default.
- W2084340632 hasConcept C143998085 @default.
- W2084340632 hasConcept C197934379 @default.
- W2084340632 hasConcept C2777288759 @default.
- W2084340632 hasConcept C2777472916 @default.
- W2084340632 hasConcept C2778375690 @default.
- W2084340632 hasConcept C2778820342 @default.
- W2084340632 hasConcept C2779490328 @default.
- W2084340632 hasConcept C29730261 @default.
- W2084340632 hasConcept C71924100 @default.
- W2084340632 hasConceptScore W2084340632C121608353 @default.
- W2084340632 hasConceptScore W2084340632C126322002 @default.
- W2084340632 hasConceptScore W2084340632C141071460 @default.
- W2084340632 hasConceptScore W2084340632C143998085 @default.
- W2084340632 hasConceptScore W2084340632C197934379 @default.
- W2084340632 hasConceptScore W2084340632C2777288759 @default.
- W2084340632 hasConceptScore W2084340632C2777472916 @default.
- W2084340632 hasConceptScore W2084340632C2778375690 @default.
- W2084340632 hasConceptScore W2084340632C2778820342 @default.
- W2084340632 hasConceptScore W2084340632C2779490328 @default.
- W2084340632 hasConceptScore W2084340632C29730261 @default.
- W2084340632 hasConceptScore W2084340632C71924100 @default.
- W2084340632 hasIssue "5" @default.
- W2084340632 hasLocation W20843406321 @default.
- W2084340632 hasLocation W20843406322 @default.
- W2084340632 hasOpenAccess W2084340632 @default.
- W2084340632 hasPrimaryLocation W20843406321 @default.
- W2084340632 hasRelatedWork W1895933560 @default.
- W2084340632 hasRelatedWork W2025444875 @default.
- W2084340632 hasRelatedWork W2033551302 @default.
- W2084340632 hasRelatedWork W2084340632 @default.
- W2084340632 hasRelatedWork W2107103442 @default.
- W2084340632 hasRelatedWork W2145046367 @default.
- W2084340632 hasRelatedWork W2571191689 @default.
- W2084340632 hasRelatedWork W2590524093 @default.
- W2084340632 hasRelatedWork W3151554875 @default.
- W2084340632 hasRelatedWork W4313210082 @default.
- W2084340632 hasVolume "20" @default.
- W2084340632 isParatext "false" @default.
- W2084340632 isRetracted "false" @default.
- W2084340632 magId "2084340632" @default.
- W2084340632 workType "article" @default.